Cardiac Radioablation vs Catheter Ablation for Rapid Heartbeat
(RADIATE-VT Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants must have failed or be intolerant to amiodarone, suggesting that changes to medication might be necessary. Please consult with the trial team for specific guidance.
Is cardiac radioablation generally safe for humans?
Cardiac radioablation (CR) is a new treatment for heart rhythm problems like ventricular tachycardia and has shown promising results. However, it involves high doses of radiation, and while there is a desire for its rapid adoption, it is important to ensure it is done safely. Some studies have noted the need for careful patient selection and monitoring to manage potential risks.12345
How is Varian Cardiac Radioablation (CRA) different from other treatments for rapid heartbeat?
Varian Cardiac Radioablation (CRA) is unique because it uses targeted radiation to treat rapid heartbeats, unlike traditional catheter ablation which uses heat or cold to destroy heart tissue causing the arrhythmia. This non-invasive approach may offer an alternative for patients who cannot undergo catheter ablation.678910
What data supports the effectiveness of the treatment Cardiac Radioablation vs Catheter Ablation for Rapid Heartbeat?
Research shows that radiofrequency catheter ablation (RFCA) is effective in treating ventricular arrhythmia (irregular heartbeats in the lower chambers of the heart), which suggests it may also be beneficial for rapid heartbeats. Additionally, catheter ablation is a well-established treatment for atrial fibrillation (a common type of irregular heartbeat), indicating its potential effectiveness for similar heart rhythm issues.57111213
Are You a Good Fit for This Trial?
This trial is for adults with a weak heart pump (LVEF ≤35%) and high-risk, stubborn ventricular tachycardia that didn't stop after previous catheter ablation. Candidates must have failed or can't tolerate amiodarone therapy, need another ablation, and have an ICD implanted. Pregnant individuals, those not using birth control, or with conditions limiting survival to under a year are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either cardiac radioablation (CRA) or repeat catheter ablation (CA) for high-risk refractory ventricular tachycardia
Follow-up
Participants are monitored for safety and effectiveness after treatment
Quality of Life Assessment
Change in quality of life assessed at 6 weeks post treatment
What Are the Treatments Tested in This Trial?
Interventions
- Catheter Ablation (CA)
- Varian Cardiac Radioablation (CRA)
Varian Cardiac Radioablation (CRA) is already approved in United States for the following indications:
- Investigational use for refractory ventricular tachycardia (VT)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Varian, a Siemens Healthineers Company
Lead Sponsor